Combining low-dose or metronomic chemotherapy with anticancer vaccines
A therapeutic opportunity for lymphomas

Heng Sheng Sow and Stephen R Mattarollo*

The University of Queensland Diamantina Institute; The University of Queensland; Translational Research Institute; Brisbane, Australia

**Keywords:** anticancer vaccines, immunotherapy, metronomic chemotherapy, low-dose chemotherapy, lymphoma

**Abbreviations:** CTL, cytotoxic T lymphocytes; DC, dendritic cell; NHL, non-Hodgkin’s lymphoma; MDSC, myeloid-derived suppressor cell; MTD, maximal tolerated dose; THBS1, thrombospondin 1; Treg, regulatory T cell; VEGF, vascular endothelial growth factor

Therapeutic vaccination is regarded as a promising strategy against multiple hematological malignancies including lymphoma. However, this approach alone possesses limited potential for the treatment of established tumors. As several anticancer regimens rely on the combination of multiple drugs, it is reasonable to predict that also cancer vaccination will be most effective in the context of multimodal approaches. In particular, low-dose or metronomic chemotherapy could be coupled to anticancer vaccines to improve the efficacy of this immunotherapeutic interventions. This review summarizes recent findings in support of the use of anticancer vaccines combined with low-dose or metronomic chemotherapy for the treatment and management of lymphoid malignancies.

**Introduction**

Lymphomas are cancers of hematological origin that can be broadly classified into a Hodgkin’s and non-Hodgkin’s variant. Although most forms of Hodgkin’s lymphoma (HL) are curable with currently available treatment modality, aggressive forms of non-Hodgkin’s lymphoma (NHL) such as diffuse large B-cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma are considered as incurable in advanced stages of the disease, and patients affected by these neoplasms undergo repeated remissions and relapses.1,2 Regardless of the subtype and stage of the disease, the treatment currently employed for most lymphomas relies on radiation therapy or combinatorial chemotherapeutic regimens that include prednisone plus the cytotoxic agents cyclophosphamide, doxorubicin, and vincristine as well as a tumor-targeting monoclonal antibody, such as the anti-CD20 agent rituximab. Such an immunotherapeutic regimen is commonly referred to as R-CHOP. Despite the enhanced overall survival exhibited by patients treated with R-CHOP, this regimen exerts substantial undesirable effects and may promote chemoresistance.3,4 Hence, less toxic and more effective modalities for the treatment of lymphoma patients are clearly needed.

Conventional chemotherapeutic agents were developed based on their capacity to directly kill malignant cells at a maximal tolerated dose (MTD), the highest amount of the drug associated with tolerable toxicity and manageable side effects. In this context, patients must go through long periods off therapy, allowing for their full recovery from the adverse effects of chemotherapy. These rest periods, however, also allow cancer cells to become resistant to chemotherapy and hence to drive a disease relapse.5 A new therapeutic paradigm has recently been established based on the administration of low-dose chemotherapeutics at short intervals (so-called, metronomic chemotherapy), in the absence of prolonged drug-free periods.6,7 Metronomic chemotherapy not only causes relatively mild and short-lived toxic effects, but also exerts an antiangiogenic activity and have been associated with robust antineoplastic effects in preclinical models of chemoresistant tumors.8 Accumulating evidence also indicates that some chemotherapeutic drugs given at a low dose are able to promote disease eradication by stimulating anticancer immune and selectively eliminating immunosuppressive cells (Table 1).9

These studies provided a rationale for using low-dose or metronomic chemotherapy as a means to counteract the numerous mechanisms of immunological tolerance that are set in place by malignant lesions, and hence improve the antitumor efficacy of therapeutic anticancer vaccination. Here, we review preclinical and clinical studies involving a panel of cytotoxic agents used in low doses or according to a metronomic schedule, either as standalone interventions or in combination with therapeutic anticancer vaccines. While focusing our attention on lymphoma-related studies, we describe how low-dose or metronomic chemotherapy may improve the potential of therapeutic anticancer vaccination (Fig. 1).
Table 1. Use of low-dose chemotherapy to overcome immunosuppression and immune evasion by lymphomas

| Escape mechanism | Effects of low-dose chemotherapeutic agents | Preclinical Studies on the Immunomodulatory Effects of Low-Dose Chemotherapy |
|------------------|-------------------------------------------|--------------------------------------------------------------------------|
| Reduced immunogenicity<sup>10,11</sup> | Cyclophosphamide, gemcitabine, doxorubicin - Promote the expression of MHC class I molecules on cancer cells<sup>12</sup> - Stimulate the exposure of calreticulin on the cell surface<sup>13,14</sup> as well as the release of HMGB1<sup>15,16</sup> and ATP<sup>14</sup> | It has recently been discovered that low-dose chemotherapy can increase the susceptibility of cancer to the cytotoxic activity of CTLs by allowing granzymes to enter target cells independently of perforin. In fact, low-dose paclitaxel, doxorubicin, and cisplatin were found to increase the permeability of cancer cells to granzyme B (GZMB) released by CTLs in vitro.<sup>15</sup> This effect was solely attributed to the ability of low-dose chemotherapy to upregulate mannose-6-phosphate (M6P) receptors on malignant cells, hence facilitating the delivery of cytotoxic GZMB molecules.<sup>15</sup> CTLs and natural killer (NK) cells also trigger the apoptotic demise of cancer cells upon the engagement of death receptors including FAS (CD95) and various members of the tumor necrosis factor α (TNFα)-related apoptosis-inducing ligand receptor (TRAILR) superfamily, with the respective ligands (e.g., FASL and TRAIL). However, several reports have revealed a marked downregulation or loss of FAS and TRAILRs in certain lymphomas, allowing malignant cells to evade the immunosurveillance mediated by CTLs and NK cells.<sup>16,17</sup> Several chemotherapeutic drugs employed at low doses have been shown to restore the expression of these death receptors. For example, a low dose of etoposide reportedly upregulates the expression of FAS on the surface of human mononuclear leukemia U937 cells, resulting in an increased FAS-dependent apoptotic response.<sup>18</sup> Low concentrations of doxorubicin or etoposide significantly increased TRAILR2 (also known as DR5) expression on human solid cancer cells, sensitizing them to TRAIL-mediated killing.<sup>19,20</sup> Along similar lines, low-dose doxorubicin restored the sensitivity to TRAIL of an originally TRAIL-resistant variant of human prostatic cancer LNCaP cells upon the upregulation of TRAILR1 (also known as DR4).<sup>21</sup> Furthermore, a single, low dose of cyclophosphamide sensitized malignant mesotheliomas to TRAIL-dependent CD8<sup>+</sup> T-cell- and NK cell-mediated cytotoxicity in vivo, resulting in the suppression of tumor growth.<sup>22</sup> |
| Apoptosis resistance upon the downregulation of FAS and TRAILRs<sup>16,17</sup> | Etoposide, doxorubicin, cyclophosphamide - Promote the upregulation of FAS<sup>14</sup> and TRAILRs<sup>16,17</sup> | Low-dose chemotherapy can increase the susceptibility of cancer to the cytotoxic activity of CTLs by allowing granzymes to enter target cells independently of perforin. In fact, low-dose paclitaxel, doxorubicin, and cisplatin were found to increase the permeability of cancer cells to granzyme B (GZMB) released by CTLs in vitro.<sup>15</sup> This effect was solely attributed to the ability of low-dose chemotherapy to upregulate mannose-6-phosphate (M6P) receptors on malignant cells, hence facilitating the delivery of cytotoxic GZMB molecules.<sup>15</sup> CTLs and natural killer (NK) cells also trigger the apoptotic demise of cancer cells upon the engagement of death receptors including FAS (CD95) and various members of the tumor necrosis factor α (TNFα)-related apoptosis-inducing ligand receptor (TRAILR) superfamily, with the respective ligands (e.g., FASL and TRAIL). However, several reports have revealed a marked downregulation or loss of FAS and TRAILRs in certain lymphomas, allowing malignant cells to evade the immunosurveillance mediated by CTLs and NK cells.<sup>16,17</sup> Several chemotherapeutic drugs employed at low doses have been shown to restore the expression of these death receptors. For example, a low dose of etoposide reportedly upregulates the expression of FAS on the surface of human mononuclear leukemia U937 cells, resulting in an increased FAS-dependent apoptotic response.<sup>18</sup> Low concentrations of doxorubicin or etoposide significantly increased TRAILR2 (also known as DR5) expression on human solid cancer cells, sensitizing them to TRAIL-mediated killing.<sup>19,20</sup> Along similar lines, low-dose doxorubicin restored the sensitivity to TRAIL of an originally TRAIL-resistant variant of human prostatic cancer LNCaP cells upon the upregulation of TRAILR1 (also known as DR4).<sup>21</sup> Furthermore, a single, low dose of cyclophosphamide sensitized malignant mesotheliomas to TRAIL-dependent CD8<sup>+</sup> T-cell- and NK cell-mediated cytotoxicity in vivo, resulting in the suppression of tumor growth.<sup>22</sup> |
| Impaired cytotoxicity of NK cells resulting from the downregulation of NKG2D ligands<sup>44,45</sup> | Dacarbazine, doxorubicin, cisplatin - Induce the expression of NKG2D<sup>29</sup> and CD226 ligands<sup>10,11</sup> | Reduced immunogenicity<sup>10,11</sup> | Cyclophosphamide, doxorubicin, paclitaxel, gemcitabine, 5-fluorouracil - Selectively kill Tregs<sup>43-45</sup> and MDSCs<sup>57-59</sup> | These findings suggest that low-dose chemotherapy can trigger the immunogenic demise of cancer cells by stimulating them to release immunostimulatory factors as they die. In this regard, Schiavoni and coworkers<sup>13</sup> found that a low concentration of the active cyclophosphamide analog mafosfamide stimulates dying tumor cells to expose calreticulin (CRT) on the cell surface and to release the nuclear protein high mobility group box 1 (HMGB1). These events were deemed as signals for the induction of innate immune responses along with the maturation and expansion of conventional CD8<sup>+</sup> DCs.<sup>15</sup> In a follow-up in vivo study, DCs from cyclophosphamide-treated mice were observed to infiltrate neoplastic lesions and to engulf apoptotic cancer cells before migrating to tumor-draining lymph nodes and eliciting a tumor-specific CTL responses through cross-priming.<sup>13</sup> Doxorubicin has also been shown to trigger immunogenic cell death by facilitating the release of ATP from dying tumor cells, resulting in the activation of DCs and in the priming of antican -

Preclinical Studies on the Immunomodulatory Effects of Low-Dose Chemotherapy

The therapeutic outcome of immunotherapy depends on the interplay between malignant cells and components of the immune system, and it is well recognized that tumors can evade immune responses by a multitude of mechanisms. Low-dose chemotherapy is likely to overcome these obstacles and hence promote the (re)establishment of antitumor immunity (Table 1). Generally, lymphomas are weakly immunogenic due to a decreased expression of MHC class I molecules on the surface of malignant cells, which prevent the recognition of tumor-associated antigens (TAA)s by cytotoxic T lymphocytes (CTLs).<sup>10,11</sup> Low-dose cyclophosphamide and gemcitabine have been shown to promote the expression of MHC class I molecules on the surface of cancer cells and thus to facilitate their antigen-dependent CTL-triggered demise.<sup>12</sup> In the same study, the culture supernatants of cancer cells treated with low-dose gemcitabine were shown to promote the maturation and activation of dendritic cells (DCs) in vitro, in turn stimulating the proliferation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells along with an increased production of interferon (IFN) γ.<sup>12</sup> These findings suggest that low-dose chemotherapy can trigger the immunogenic demise of cancer cells by stimulating...
normal cells, but are expressed on the surface of stress, infected or malignant cells. Lymphoma patients often exhibit decreased NK-cell activity, resulting in impaired cytotoxicity against malignant cells. It has been reported that malignant lymphomas are characterized by a significant downregulation of the NKG2D ligand MHC class I polypeptide-related sequence A (MICA) as this sheds from the plasma membrane, and patients with elevated circulating levels of MICA and similar molecules exhibit impaired NK-cell function. Upon exposure to low-dose doxorubicin and cisplatin, multiple myeloma cells exhibit an increase susceptibility to NK-cell cytotoxicity, at least in part due to the upregulation of ligands for NKG2D and CD226, which is also involved in NK cell-mediated tumor cell killing.

Several cytokines including IFNα, interleukin (IL)-2, IL-12, and IL-15 have been shown to upregulate NKG2D receptors, a process that is associated with an amplification of NKG2D-mediated antitumor response. Interestingly, low-dose...
cyclophosphamide has been reported to stimulate the expression of type I IFNs, i.e., IFNα and IFNβ, which are important stimuli for the proliferation and persistence of CD8+ T cells.35 Mice pretreated with low-dose cyclophosphamide were also found to produce immunostimulatory cytokines including IL-1β, IL-2, IL-7, IL-15, IL-21, IFNγ, and granulocyte macrophage colony-stimulating factor (GM-CSF), while secreting decreased amounts of immunosuppressive cytokines, such as IL-4 and IL-10. These immunological effects of low-dose cyclophosphamide exacerbated the antineoplastic potential of adoptively transferred immune cells against melanoma.36 Taken together, these observations indicate that some cytotoxic drugs such as cyclophosphamide at low doses can enhance the secretion of immunostimulatory cytokines, which in turn promote the expression of NKG2D receptors on the surface of NK cells to ultimately boost antitumor immunity.

### Selective Eradication of Immunosuppressive Cell Populations by Low-Dose Chemotherapy

#### Regulatory T cells

Regulatory T cells (Tregs), which constitute about 5% of peripheral CD4+ T cells in both mice and humans, play a key role in the maintenance of peripheral tolerance and prevent the emergence of pathological autoimmune reactions.37 In tumor-bearing hosts, Tregs facilitate disease progression by curtailing NK and T-cell immunity through various mechanisms, including the expression of the inhibitory checkpoint regulator cytotoxic T lymphocyte-associated protein 4 (CTLA4) on their surface and the production of immunosuppressive mediators such as IL-10 and transforming growth factor β1 (TGFβ1).38-40 Notably, lymphoma patients exhibit elevated levels of Tregs, and this contributes to the resistance of malignant cells to immunosurveillance.41,42 Interventions aimed at enhancing antitumor immune responses based on the depletion or neutralization of Tregs by chemotherapy have been intensively studied. Thus, low-dose cyclophosphamide was found to selectively kill Tregs in vivo, in a murine model of lymphoma.43 In this setting, effector T cells were activated along with Treg depletion and increased expression of IL-2.43 When mice with colon cancer were treated with low-dose cyclophosphamide plus doxorubicin, a significant suppression of tumor growth was associated with Tregs depletion and decreased secretion of TGFβ1 within the tumor microenvironment.44 Another study has demonstrated that low-dose paclitaxel decreases the viability of Tregs and their capacity to produce immunosuppressive cytokine in vivo, in a murine model of lung cancer, while leaving conventional T cells untouched.45

#### Myeloid-derived suppressor cells

Under steady-state conditions, highly plastic immature myeloid cells arise from multipotent hematopoietic stem cells (HSCs) and develop into mature macrophages, dendritic cells, and granulocytes with diverse functions, through sequential steps of differentiation.46 Conversely, factors produced in the tumor microenvironment interfere with normal myelopoiesis, resulting in the accumulation of immature myeloid cells that exert immunosuppressive functions, which are cumulatively known as myeloid-derived suppressor cells (MDSCs), in the circulation, lymphoid tissues as well as within neoplastic lesions.37 In tumor-bearing mice, co-expression of surface markers Gr-1+ and CD11b+ are commonly found on MDSCs.47 In humans, 2 major MDSC subsets have been characterized: CD11b+D14’HLA-DR+CD33’CD124+ monocytic MDSCs (M-MDSCs) and, CD11b+CD14’CD66b’CD15’CD124+ granulocytic/polymeronuclear MDSCs (G-MDSCs/PMN-MDSCs).48-49 The accumulation of these MDSCs in the peripheral blood and within neoplastic lesions has been reported in a large number of cancer patients.49-51 MDSCs suppress innate and adaptive antitumor immune responses by favoring the recruitment and expansion of Tregs, as well as by producing high levels of L-arginase, reactive oxygen species (ROS), inducible nitrogen oxide synthase (iNOS), and various immunosuppressive cytokines. Overall, these enzymes and soluble mediators promote neoangiogenesis and allow for the escape of immune cells from immunosurveillance, hence promoting disease progression.48,52-54 Of note, in lymphoma patients, an increased frequency of circulating MDSCs has been reported to correlate with aggressive disease and the inhibition of antitumor immunity.55,56

Clearly, both these immunosuppressive cell populations must be inhibited or eliminated in order to restore therapeutically-relevant antitumor immune responses. Some low-dose or metronomic chemotherapeutic regimens have been shown to selectively kill immunosuppressive cell populations. For example, low-dose gemcitabine appears to selectively inhibit tumor-associated MDSCs in mice bearing 4T1 mammary carcinomas, favoring the expansion of tumor-targeting T cells.57 Along similar lines, low-dose 5-flourouracil has been shown to provoke a major decrease in splenic and tumor-infiltrating MDSCs in mice bearing EL4 thymomas while leaving T cells, NK cells, dendritic cells, and B cells unaffected.58 Interestingly, the elimination of MDSCs by 5-flourouracil was associated with a boost in antitumor immunity, manifesting with an increment in IFNγ production by tumor-specific CD8+ T cells.59 Of note, metronomic chemotherapy with low-dose cyclophosphamide and gemcitabine has been demonstrated to deplete tumor-associated Tregs and MDSCs in mice bearing CT26 colon carcinomas, leading to antitumor T-cell response and tumor eradication, at least in some animals.59 As previously mentioned, doxorubicin is known for its ability to induce immunogenic cell death by allowing for the release of ATP from dying cancer cells and hence favoring the elicitation of antitumor immune responses.14 The release of ATP from malignant cells succumbing to doxorubicin was found to induce the differentiation of tumor-infiltrating myeloid cells toward CD11c+CD11b+Ly6G+ cells sharing some features with DCs, including the ability to efficiently engulf TAAs in situ and to elicit cellular immune responses against cancer cells.60 Taken together, these observations suggest that low-dose chemotherapy is a promising approach to restore antitumor immunity by eliminating or inhibiting immunosuppressive Tregs and MDSCs, thus promoting the differentiation of antigen-presenting cells and the elicitation of tumor-targeting CTL responses.
Anti-Angiogenic Effects of Low-Dose or Metronomic Chemotherapy

The expansion of the tumor vasculature is vital for the growth of hematological malignancies and increased angiogenesis is often correlated with poor prognosis in lymphoma patients. The major mediator of the angiogenic switch is vascular endothelial growth factor (VEGF), which is produced by lymphoma cells and binds VEGF receptors expressed on endothelial cells from pre-existing capillaries as well as on circulating endothelial precursor cells of bone marrow derivation. Metronomic chemotherapy has been shown to mediate beneficial anti-angiogenic effects. For example, Browder et al. administered cyclophosphamide on a metronomic schedule to mice affected by Lewis lung carcinoma or L1210 leukemia, and observed a substantial apoptotic response among endothelial cells of the growing tumor vasculature, resulting in the inhibition of angiogenesis. This effect was lost when the drug was given at the MTD. In addition, metronomic cyclophosphamide was 3 times more effective than the same drug given as a standard regimen in treating neoplastic lesions developing from cancer cells that had been made cyclophosphamide-resistant before inoculation.

Adopting the same metronomic schedule, Hamano et al. found that the anti-angiogenic effect of low-dose cyclophosphamide is mediated by the selective upregulation of thrombospondin 1 (THBS1) in malignant cells and tumor-associated endothelial cells. THBS1 is an endogenous inhibitor of angiogenesis that arrests the proliferation and triggers the apoptotic demise of endothelial cells. This finding was supported by results from Bocci and colleagues, who observed that the plasma of SCID mice bearing human tumors contains higher levels of THBS1 upon the administration of metronomic low-dose cyclophosphamide. Most importantly, the anti-angiogenic and antitumor effects of metronomic cyclophosphamide were diminished in Thbs1−/− mice, further corroborating the notion that THBS1 is a pivotal mediator of the therapeutic activity of low-dose cyclophosphamide. In addition, Bertolini et al. reported that the administration of metronomic cyclophosphamide to mice harboring human lymphomas decreases the abundance and viability of endothelial precursor cells, resulting in a significant reduction of tumor growth as compared with cyclophosphamide given at its MTD. Furthermore, metronomic doxorubicin as well as metronomic cisplatin have been shown to reduce the expression of VEGF, leading to a significant inhibition of tumor growth in murine models of adenocarcinoma and hepatocarcinoma.

Preclinical and Clinical Studies of Low-Dose Chemotherapy Alone and in Combination with Anticancer Vaccines

The efficacy of low-dose chemotherapy against lymphoma has been demonstrated in several preclinical studies. Mice bearing A20 lymphomas exhibited a prolonged survival and reduced rates of tumor growth upon treatment with low-dose cyclophosphamide (20 mg/kg). Bertolini et al. also observed a significant inhibition of tumor growth in mice bearing human mantle lymphomas upon the administration of cyclophosphamide in drinking water as a continuous low-dose of 20 mg/kg/day. In rat models of lymphoma, Rozados et al. showed that the metronomic administration of low-dose cyclophosphamide (10 mg/kg) i.p. results in tumor eradication in the absence of overt toxicity. This finding indicates that metronomic chemotherapy is an effective and safe alternative to conventional anticancer regimens.

Based on the results of these and other preclinical studies, numerous clinical trials have assessed the antineoplastic profile of metronomic chemotherapy in lymphoma patients. For instance, a regimen consisting of daily low-dose lomustine and chlorambucil, daily subcutaneous bleomycin and vincristine, plus methotrexate and dexamethasone given on an eight-week cycle (LBCMVD-56) has been evaluated in patients with refractory/relapsed lymphoma. The overall response rate (ORR) of these patients was 67%, encompassing 21% of complete responses (CRs), with a median overall survival of 13 mo. In a similar approach, Coleman et al. reported the clinical efficacy of continuous, low-dose oral prednisone (20 mg), etoposide (50 mg), procarbazine (50 mg), and cyclophosphamide (50 mg) (PEP-C) administered either daily, on alternate days, or on a fractionated basis, in heavily pretreated patients with refractory/relapsed lymphoma. In this study the ORR was 75%, 38% of patients achieved a CR, and minimal toxicity was reported. These clinical findings demonstrate that continuous low-dose chemotherapy is effective and well-tolerated by lymphoma patients. Objective responses and prolonged progression-free survival have also been reported among Hodgkin’s lymphoma patients treated with a combination of low-dose daily oral cyclophosphamide, weekly vinblastine and rofecoxib. As demonstrated in both preclinical and clinical settings, the efficacy of metronomic chemotherapy mainly relies on anti-angiogenic effects coupled to the selective eradication of Tregs, enabling the restoration of antitumor T-cell and NK-cell activity.

Therapeutic vaccines, given their specificity, low toxicity and capability to harness the patient’s immune system to fight cancer, are being recognized as a potential complementary approach against solid and hematopoietic malignancies. Therapeutic vaccination is an active form of immunotherapy that can promote the elicitation of tumor-specific cellular immune responses, the production of tumor-targeting polyclonal antibodies as well as the establishment of memory immune responses against multiple TAAs, hence limiting the emergence of tumor immune escape variants. In a pilot study, Di Nicola et al. vaccinated indolent NHL patients undergoing disease relapse with autologous dendritic cells loaded with tumor cells. At a median follow-up of 50.5 mo, 6 out of 18 patients manifested objective clinical responses including 3 CRs and 3 partial responses (PRs). Impressively, clinical responses were associated with a reduction in the levels of Tregs coupled to the induction of NK, T, and B-cell responses. BiovaxID, a patient-specific therapeutic anti-idiotype (ID) lymphoma vaccine conjugated to keyhole limpet hemocyanin (KLH), has recently been shown to provide clinical benefits to patients in a phase III study. At a median follow-up of 56.6 mo, the administration of ID-KLH together with GM-CSF to follicular lymphoma patients achieving a CR upon chemotherapy
was associated with an impressive disease-free survival of 44.2 mo, compared with 30.6 mo for the control arm. Nevertheless, it is becoming apparent that anticancer vaccines administered as standalone therapeutic interventions have limited potential for the treatment of established tumors, owing to the intrinsic and/or acquired ability of neoplastic lesions to suppress the antitumor immune responses that are elicited by vaccination. Hence, low-dose or metronomic chemotherapy might be used in conjunction with anticancer vaccines in order to promote beneficial immunomodulatory effects and abrogate tumor-induced immunosuppression, thereby boosting vaccine-induced immune responses and achieving therapeutically-relevant antineoplastic effects.

The proof-of-principle in support of the use of this combinatorial immunoncchemotherapeutic strategy in lymphoma patients has been provided in a study in which a dendritic cell-based vaccine coupled to low-dose cyclophosphamide for 2 consecutive days was given to mice bearing A20 lymphomas, resulting in a significant improvement of survival and complete, long-term tumor regressions. Moreover, most of the mice in which the primary tumor was eradicated by combinatorial immunomotherapy were resistant to a secondary tumor challenge, pointing to the development of long-lasting memory T-cell responses in response to vaccination. This approach was also shown to be effective at eradicating tumors that recurred after a period of regression following the initial vaccination. Along similar lines, a combination of low-dose cyclophosphamide and oligodeoxynucleotides containing unmethylated CG sequences administered intratumorally cured widely disseminated B-cell lymphomas in mice. The authors of this study found that CpG oligodeoxynucleotides enhance the presentation of TAAs by local DCs and hence induce tumor-specific CD8+ T-cell responses that are able to eradicate large and systemic lymphomas.

Our group has investigated the efficacy of combining metronomic cyclophosphamide with an NKT cell adjuvant-based vaccine against Eµ-myc-driven B-cell lymphomas in mice. In this setting, a single therapeutic vaccination with irradiated, α-galactosylceramide-loaded autologous tumor cells induced a large systemic spike of IFNγ coupled to a transient expansion of peripheral NKT and NK cells, globally leading to the suppression of tumor growth and to a prolonged protection against Eµ-myc-driven lymphoma. However, the therapeutic response to the vaccine was not durable and most mice succumbed to delayed disease relapse. In our latest study, cyclophosphamide was given to mice bearing Eµ-myc-driven lymphoma according to metronomic low-dose regimen (5 mg/kg, on alternative days for 2 weeks) prior to vaccination, in order to investigate the benefits of such a combinatorial immunoncchemotherapeutic approach. In preliminary experiments, mice that received cyclophosphamide followed by the NKT cell adjuvant-based vaccine were cured from disease, with no evidence of relapse. Conversely, mice treated with either the vaccine or metronomic chemotherapy alone succumbed to the lymphoma (Heng Sheng Sow, personal communication). These findings suggest that metronomic chemotherapy can enhance the efficacy of NKT adjuvants against B-cell lymphoma. The mechanisms underlying these effects, however, remain to be determined.

Published preclinical observations and our preliminary findings provide a rationale for combining low-dose or metronomic chemotherapy with anticancer vaccination for treating lymphoma. However, to the best of our knowledge, no clinical studies published so far have evaluated this strategy in lymphoma patients. Conversely, the therapeutic efficacy of this combinatorial immunoncchemotherapeutic approach has been explored in patients bearing solid tumors. Enhanced vaccine-induced immune responses have been observed in breast carcinoma patients treated with an allogeneic GM-CSF-secreting vaccine along with low doses of cyclophosphamide, given one day prior to vaccination, and doxorubicin, administered 1 week later. Moreover, the combination of metronomic cyclophosphamide with methotrexate and a 1E10 anti-idiotype vaccine has been reported to increase the clinical responses achieved by patients with metastatic breast cancer. Kandalaf et al. reported that the combination of a dendritic cell-based autologous vaccine with bevacizumab and metronomic cyclophosphamide provides clinical benefits to advanced recurrent ovarian cancer patients. In light of the feasibility and potential clinical activity demonstrated by this approach in patients with solid tumors, the possible therapeutic benefits of active immunotherapy and low-dose or metronomic chemotherapy for lymphoma patients are worthy further investigation.

Concluding Remarks

As demonstrated in multiple preclinical and clinical studies, including those discussed in this review, the multipronged immunostimulatory effects and good safety profile of low-dose or metronomic chemotherapy have gradually led to its use in cancer patients as an alternative to chemotherapy based on conventional doses and administration schedules. We speculate that low-dose or metronomic chemotherapy used in combination with therapeutic anticancer vaccines or other forms of immunotherapy will ameliorate disease outcomes as compared with standard, high-dose chemotherapy or immunotherapy administered as a standalone intervention. Additional studies are required to determine the repertoire of immunostimulatory effects mediated by various cytotoxic agents given at low doses or according to a metronomic schedule as well as the optimal dosage, delivery route, and schedule at which such effects can be obtained for combining these drugs with anticancer vaccines. The combination of anticancer vaccines with low-dose chemotherapy nowadays stands out as a promising therapeutic approach against a range of neoplasms, including lymphomas.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest have been disclosed.
References

1. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012; 380:848-57; PMID:22835603; http://dx.doi.org/10.1016/S0140-6736(12)60605-9

2. Gandhi MK, Marcus RE. Follicular lymphoma: time for a re-think? Blood Rev 2005; 19:165-78; PMID:15786946; http://dx.doi.org/10.1016/j.blre.2004.09.002

3. Hiddemann W, Keube M, Dreyle M, Schmitz N, Lengfelder E, Schmitz R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725-32; PMID:16212323; http://dx.doi.org/10.1182/blood-2005-01-0016

4. Krause SW, Gerken M, Andreesen R, Hofstadler F, Klinkhammer-Schalke M. Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit in patients treated in the routine data of a regional cancer registry. Ann Hematol 2012; 91:561-70; PMID:22200972; http://dx.doi.org/10.1007/s00270-011-1361-6

5. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005; 5:516-25; PMID:15964934; http://dx.doi.org/10.1038/nrc1650

6. Gasparini G. Metronomic scheduling: the future of chemotherapy? Cancer Sci 2008; 100:97-107; PMID:18369619; http://dx.doi.org/10.1111/j.1349-7006.2008.00505.x

7. Mross K, Steinbild S. Metronomic anti-cancer therapy – an ongoing treatment option for advanced cancer patients. journal of Cancer Therapeutics and Research 2012:1

8. Bowelder T, Butterfeld CE, Kraling BM, Shi B, Marshall B, O’Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2009; 69:1088-86; PMID:19766175

9. Ménard C, Martin F, Apetoh L, Bouyer F, Belardelli F, Proietti E. Cyclophosphamide enhances the maturation of CD4+CD25- T-cells in normal human lymphoid tissue. Blood 2001; 98:2847-54; PMID:11667786; http://dx.doi.org/10.1182/blood-2001-04-1025

10. Groh V, Wu Y, Jee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Int Immunopharmacol 2008; 8:475-84; PMID:18328470; http://dx.doi.org/10.1016/j.intimp.2008.02.003

11. Ménard C, Martin F, Apetoh L, Bouyer F, Belardelli F, Proietti E. Cyclophosphamide enhances the maturation of CD4+CD25- T-cells in normal human lymphoid tissue. Blood 2001; 98:2847-54; PMID:11667786; http://dx.doi.org/10.1182/blood-2001-04-1025

12. Groh V, Wu Y, Jee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Int Immunopharmacol 2008; 8:475-84; PMID:18328470; http://dx.doi.org/10.1016/j.intimp.2008.02.003

13. Zocchi MR, Castellani S, Canevalli P, Taillav S, Garuti A, Villaggio B, Zanino A, Gobbi M, Fraternali-Oricioni G, Kunkl A, et al. High ERPs/ ADAM10 expression in lymph node microenvironment and impaired NGK2D ligands recognition in Hodgkin lymphomas. Blood 2012; 119:1479-89; PMID:22167753; http://dx.doi.org/10.1182/blood-2011-07-370841

14. Acemovic L, Aperoht L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G, Smyth MJ, Zitvogel L. Tumor cell death and ATP release prime dendritic cells and efficient antitumor immunity. Cancer Res 2010; 70:855-8; PMID:20068177; http://dx.doi.org/10.1158/0008-5472.CAN-09-3566

15. Ramakrishnan R, Assudani D, NagaSarjani S, Hunter T, Cho Hl, Antonia S, Aliot S, Celsi E, Gabrielovich DI. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immuno-therapy in mice. J Clin Invest 2010; 120:1111-24; PMID:20254093; http://dx.doi.org/10.1172/JCI40269

16. Zoi-Toli O, Vermeer MH, De Vries V, Van Beek P, Meijer CJ, Willemsen R. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 2001; 144:313-9; PMID:11953118; http://dx.doi.org/10.1046/j.1365-2141.2000.01986.x

17. Akiyama H, Ino T, Tokunaga E, Katsuda S, Azumi K. A synergistic increase of apoptosis utilizing Fas antigen expression induced by low doses of anticancer drug. Rinsho Byori 2001; 51:733-9; PMID:13677932

18. Wu XX, Jin XH, Zeng Y, El Hamed AM, Kakehi Y. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Cancer Sci 2007; 98:1979-86; PMID:17922852; http://dx.doi.org/10.1111/j.1349-7006.2007.00632.x

19. Matarollo SR, Kenna T, Nieda M, Nicoli AJ. Chemotherapy pretreatment sensitizes solid tumor-derived cell line cells to V alpha 24 + NK cell-medi- ated cytoxicity. Int J Cancer 2006; 119:1630-7; PMID:16646079; http://dx.doi.org/10.1002/ijc.21209

20. Kang J, Bu J, Hao Y, Chen F. Subsonic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Cancer Prostate Cancer Dis 2005; 8:274-9; PMID:15897917; http://dx.doi.org/10.1038/jpacin.2005.39

21. van der Most RG, Currie AJ, Cleaver AL, Sirmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BWS, Smyth MJ, et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent cell death, resulting in suppression of tumor growth. PLoS One 2009; 4:e9682; PMID:19746156; http://dx.doi.org/10.1371/journal.pone.0009682

22. Waldhauser I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008; 27:5932-43; PMID:18836474; http://dx.doi.org/10.1038/onc.2008.267

23. Konjievij G, Jurisić V, Bančićević B, Spuzić I. The difference in NK-cell activity between patients with non-Hodgkin's lymphomas and Hodgkin's disease. Br J Haematol 1999; 104:144-51; PMID:10027772; http://dx.doi.org/10.1046/j.1365-2457.1999.01129.x

24. Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reisch U, Hucker C, Kohl U, Durkop H, Engert A, et al. Rescue of impaired NK cell activity in Hodgkin lymphoma with biodegradable antibodies in vitro and in patients. Molecular therapy: the journal of the American Society of Gene Therapy 2013; 21:895-903; http://dx.doi.org/10.1038/mte.2013.14

25. Schiavoni G, Mattei F, D’Urso MT, Belardelli F, et al. Cyclophosphamide synergizes with type I interferon through systemic dendritic cell reactivation and induction of immunogenic tumor apop- tosis. Cancer Res 2011; 71:768-78; PMID:21566650; http://dx.doi.org/10.1158/0008-5472.CAN-10-2788

26. Armitage JO, Shankland KR. Non-Hodgkin lymphoma. Lancet 2012; 380:848-57; PMID:22835603; http://dx.doi.org/10.1016/S0140-6736(12)60605-9
41. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immune-suppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103:1755-62; PMID:14609457; http://dx.doi.org/10.1182/blood-2003-07-2594

42. Mittal S, Marshall NA, Duncan L, Culligan DJ, Barker RN, Vickers MA. Local and systemic induc- tion of CD4+CD25+ regulatory T cells governing by non-Hodgkin lymphoma. Blood 2008; 113:539-70; PMID:18305220; http://dx.doi.org/10.1182/blood-2007-08-103595

43. Dou AX, Feng LL, Liu XQ, Wang X. Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model. Cell Mol Immunol 2012; 9:482-8; PMID:23006689; http://dx.doi.org/10.1038/cmi.2012.34

44. Tongu M, Harashima N, Yamada T, Harada M. Monocytogenes lymphoma with cyclophosphamide and doxorubicin against established murine carcinoma. Cancer Immunol Immunother 2010; 59:769-77; PMID:19940990; http://dx.doi.org/10.1007/s00262-009-0797-1

45. Zhu Y, Liu N, Xiong SD, Zhong YJ, Cha YW. CD4+Foxp3+ regulatory T-cell impairment by paxi-taxel is independent of toll-like receptor 4. Scand J Immunol 2011; 73:301-8; PMID:21223350; http://dx.doi.org/10.1111/j.1365-3083.2011.02514.x

46. Gschöllková S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19179274; http://dx.doi.org/10.1038/nri2506

47. Movahedi K, Guilliams M, Van den Bossche J, Van den Berg R, Gysens C, Beschin A, De Baetselier P, et al. CCR5-dependent identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111:4233-44; PMID:18272812; http://dx.doi.org/10.1182/blood-2007-07-099226

48. Youn JJ, Kamar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, McCaffrey JC, Fishman M, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentialism of myeloid cells in cancer. Nat Immunol 2011; 12:239-46; PMID:21355483; http://dx.doi.org/10.1038/nm.2356

49. Goret TF, Manns MP, Korangy F. Myeloid-derived suppressor cells in human diseases. Int Immunopharmacol 2011; 11:802-7; PMID:21232799; http://dx.doi.org/10.1016/j.intimp.2011.01.003

50. Brandau S, Trellakis S, Bruderek K, Schmalitz D, Steller G, Elan M, Suttmann H, Schenck M, Welling J, Zabel P, et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 2011; 89:311-7; PMID:21016641; http://dx.doi.org/10.1189/jlb.0310162
74. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011; 29:2787-94; PMID:21632504; http://dx.doi.org/10.1200/JCO.2010.33.3005

75. Song W, Levy R. Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res 2005; 65:5958-64; PMID:15994975; http://dx.doi.org/10.1158/0008-5472.CAN-05-0406

76. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol 2007; 179:2493-500; PMID:17675511

77. Mattarollo SR, West AC, Stregh K, Duret H, Pager C, Martin B, Matthews GM, Shortt J, Chesi M, Bergsagel PL, et al. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood 2012; 120:3019-29; PMID:22932803; http://dx.doi.org/10.1182/blood-2012-04-426643

78. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009; 27:5911-8; PMID:19805669; http://dx.doi.org/10.1200/JCO.2009.23.3494

79. Soriano JL, Batista N, Santiesteban E, Lima M, González J, García R, Zarza Y, López MV, Rodríguez M, Loys JL, et al. Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer. Int J Breast Cancer 2011; 2011:710292; PMID:22295231; http://dx.doi.org/10.4061/2011/710292

80. Kandalaft LE, Powell DJ Jr., Chiang CL, Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Tongiann DA, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncol Immunology 2013; 2:e22664; PMID:23482679; http://dx.doi.org/10.4161/onci.22664